CN1895261A - Use of pokeroot saponin A in preparation medicine for treating rheumatoid arthritis - Google Patents
Use of pokeroot saponin A in preparation medicine for treating rheumatoid arthritis Download PDFInfo
- Publication number
- CN1895261A CN1895261A CN 200610028041 CN200610028041A CN1895261A CN 1895261 A CN1895261 A CN 1895261A CN 200610028041 CN200610028041 CN 200610028041 CN 200610028041 A CN200610028041 A CN 200610028041A CN 1895261 A CN1895261 A CN 1895261A
- Authority
- CN
- China
- Prior art keywords
- rheumatoid arthritis
- pokeroot saponin
- group
- pokeroot
- saponin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
An application of the esculentoside A in preparing the medicine or food for treating rheumatoid arthritis is disclosed. Its chemical structure is also disclosed.
Description
Technical field
The present invention relates to medical technical field, is that pokeroot saponin A is used to prepare the purposes for the treatment of medicine for treating rheumatoid arthritis.
Background technology
The Chinese medicine Radix Phytolaccae is the dried root of Phytolaccaceae plant Phytolacca esculenta (P.acinosa) or pokeroot Phytolacca Americana, the Chinese medicine of including for all previous Chinese Pharmacopoeias.Nature and flavor hardship, cold, poisonous.The traditional Chinese medical science is used for removing water retention by purgation eliminating stagnation, reducing swelling and alleviating pain.Cure mainly edema, distension, sore throat, carbuncle, malignant boil.But never be used to treat rheumatoid arthritis.Pokeroot saponin A is a kind of main component (Yi Yanghua etc., the Chinese herbal medicine 1984,15 (2): 7) in the esculentoside constituents that is separated to from Radix Phytolaccae.Its chemical constitution is as follows:
We studies show that pokeroot saponin A is effective to multiple mice inflammatory model, but do not see that so far pokeroot saponin A has the report of therapeutical effect to rheumatoid arthritis.
Summary of the invention
The invention provides a kind of pokeroot saponin A and be used to prepare the purposes for the treatment of medicine for treating rheumatoid arthritis.
Find that through animal experiment pokeroot saponin A has significant therapeutical effect to rheumatoid arthritis.Test as follows: the animal of selecting for use is the DBA/1J mice, and the method that adopts U.S. Chondrex company to describe is induced and set up the rheumatoid arthritis mouse model.Mice is divided into 6 groups at random: normal group, model group, positive controls, the high, medium and low dosage group of pokeroot saponin A.The positive contrast medicine of Radix Tripterygii Wilfordii lactone alcohol, each dosage group of Esculentoside A,B,C,D is the same with positive controls, and arthritic volume all has significantly than model group and dwindles, and the difference (P＜0.01) of biostatistics's meaning of highly significant is arranged.And Esculentoside A,B,C,D is dosage-effect relation to the effect of dwindling rheumatoid arthritis knuckle swelling.Esculentoside A,B,C,D can be used for preparing the medicine or the food for the treatment of rheumatoid arthritis.
The specific embodiment
Now the experiment to the therapeutical effect of rheumatoid arthritis is described in detail to pokeroot saponin A:
Positive control drug is Radix Tripterygii Wilfordii lactone alcohol (Triptolide, TPL) (U.S. Pharmagenesis pharmaceutical factory provides).TPL is a kind of main component of traditional resisting rheumatoid arthritis Chinese medicine Radix Tripterygii Wilfordii, has the activity of significant resisting rheumatoid arthritis.1.Chen BJ.Triptolide，a novelimmunosuppressive and anti-inflammatory agent purified from a Chinese herbTripterygium wilfordii Hook F.Leuk Lymphoma.2001；42：253-265.2.Gu WZ，ChenR，Brandwein S，McAlpine J，Burres N.Isolation，purification，and characterization ofimmunosuppressive compounds from tripterygium：triptolide and tripdiolide.Int JImmunopharmacol.1995 May；17(5)：351-6.
The model reference substance is normal saline (a self-control back sterilization)
One, animal subject
1. originate: U.S. Jackson Company of Animals Ltd.
2. kind strain: DBA/1J mice
3. the animal quality certification: 2006-D128 number
4. body weight: 17-20g
5. sex: male and female half and half
6. raising condition:
23 ± 2 ℃ of animal housing's temperature, relative humidity are 65-75%, and 12/ hour brand-new wind of ventilation volume was controlled illumination 12 hours automatically, and the cage tool sterilizes twice weekly, and pad sterilization wood flour is raised with standard feed in it, freely drinks water.
Two, animal grouping
Mice is divided into 6 groups at random: normal group, model group, positive controls, the high, medium and low dosage group of pokeroot saponin A.Except normal group, other mice is all brought out into earlier the rheumatoid arthritis model, distinguishes drug treatment again.
Three, experimental technique
1. rheumatoid arthritis mouse model preparation: the method that adopts U.S. Chondrex company to describe is induced and is set up the rheumatoid arthritis mouse model.Concrete steps are as follows: cattle II Collagen Type VI is mixed with the solution of 2mg/ml with 0.05M acetic acid, 4 ℃ of stirred overnight until dissolving fully ,-20 ℃ of preservations.By the consumption of every mice 100 μ g cattle II Collagen Type VIs calculating collagen, tissue refiner fully mixes cattle II Collagen Type VI and isopyknic Fo Shi Freund's complete adjuvant (tuberculin that contains 1mg/ml) on ice-water bath, forms Emulsion.Splash into an Emulsion in one glass of clear water, emulsion droplet maintains the original state, the not dispersive qualified stability that is considered to.Injection 0.1ml Emulsion is subcutaneous at the afterbody of mice.At the 21st day, the reuse Freund incomplete adjunvant replaced Fo Shi Freund's complete adjuvant preparation Emulsion, at subcutaneous this Emulsion of another location injection 0.1ml of afterbody.After immune 4 weeks for the first time, mouse arthritis begins to produce, and 6-8 week reaches the most serious degree.
2. grouping is divided into according to body weight at random with dosage: 15 of normal group; 15 of model group; 15 of positive controls; Each 15 of high, medium and low dosage groups.Normal group is a normal mouse, not administration.After all the other each groups all cause the rheumatoid arthritis mouse model earlier, administration respectively again.Model group and pokeroot saponin A administration group be in every morning per os gastric infusion 1 time, each 0.1ml/20g body weight.Model group: wait capacity 0.9% normal saline; Pokeroot saponin A low dose group: 10mg/kg; Dosage group: 15mg/kg in the pokeroot saponin A; Pokeroot saponin A high dose group: 22.5mg/kg; Radix Tripterygii Wilfordii lactone alcohol (Triptolide, TPL) positive controls: the 0.2mg/Kg intravenously administrable, inferior on every Wendesdays.From back continuous 28 days of immunity for the second time.After 4 weeks of administration, with its arthritic arthritic volume of kind of calliper (length * wide * high mm
3).With animals administer posterior joint volume is curative effect index, obtains the suppression ratio behind each animal-use drug.
Press the biological data statistical method and handle, (significance of rheumatoid arthritis cyst volume difference in size before and after the medication is estimated in X ± SD) and t check carrying out biostatistics's analysis to means standard deviation.The results are shown in Table 1
Table 1 Esculentoside A,B,C,D is to the therapeutic outcome of mice rheumatoid arthritis
| Group | Number of animals (only) | Arthritic volume (mm 3) | Joint on average increase value (mm 3) | Suppression ratio % | |
| Before the administration | After the administration | ||||
| Normal group model group positive controls (0.2mg/kg) Esculentoside A,B,C,D 22.5mg/kg 15mg/kg 10mg/kg | 15 15 15 15 15 15 | 10.39+1.19 10.58±1.22 10.66±1.62 10.32±1.07 10.04±1.02 10.56±1.23 | 12.68±1.89 18.42±3.89 14.55±2.11 13.20±2.25 13.71±1.16 14.53±1.81 | +2.29±1.34 +7.84±2.31 +3.89±1.86 * +2.80±2.06 * +3.67±1.83 * +4.00±1.57 * | 71.1 90.8 75.1 69.2 |
* compare P＜0.01 with model group
The normal group mice is under not administration condition, and the joint physiological is grown up.Model group is after only giving normal saline, and arthritic volume enlarges markedly and each dosage group of Esculentoside A,B,C,D is the same with positive controls, and arthritic volume all has than model group and significantly dwindles, and the difference (P＜0.01) of biostatistics's meaning of highly significant is arranged.And Esculentoside A,B,C,D is dosage-effect relation to the effect of dwindling rheumatoid arthritis knuckle swelling.Esculentoside A,B,C,D can be used for preparing the medicine or the food for the treatment of rheumatoid arthritis.
Claims (1)
1. pokeroot saponin A is in the medicine or the Application in Food of preparation treatment rheumatoid arthritis, and the chemical structural formula of said pokeroot saponin A is as follows:
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200610028041 CN1895261A (en) | 2006-06-22 | 2006-06-22 | Use of pokeroot saponin A in preparation medicine for treating rheumatoid arthritis |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 200610028041 CN1895261A (en) | 2006-06-22 | 2006-06-22 | Use of pokeroot saponin A in preparation medicine for treating rheumatoid arthritis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1895261A true CN1895261A (en) | 2007-01-17 |
Family
ID=37607998
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 200610028041 Pending CN1895261A (en) | 2006-06-22 | 2006-06-22 | Use of pokeroot saponin A in preparation medicine for treating rheumatoid arthritis |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1895261A (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102030811A (en) * | 2010-11-23 | 2011-04-27 | 中国人民解放军第二军医大学 | Phytolaccagenin derivative and preparation method and application thereof |
| CN110559348A (en) * | 2019-08-21 | 2019-12-13 | 沈阳药科大学 | Composition with hederagenin A1 as active ingredient and application thereof |
-
2006
- 2006-06-22 CN CN 200610028041 patent/CN1895261A/en active Pending
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102030811A (en) * | 2010-11-23 | 2011-04-27 | 中国人民解放军第二军医大学 | Phytolaccagenin derivative and preparation method and application thereof |
| CN110559348A (en) * | 2019-08-21 | 2019-12-13 | 沈阳药科大学 | Composition with hederagenin A1 as active ingredient and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105362295A (en) | Periplaneta americana pharmaceutical composition for treating acute and chronic faucitis and dental ulcers and preparation method thereof | |
| CN103495136B (en) | A kind ofly treat fermentation of Chinese herbal medicine of gastrointestinal tract of livestock and fowls parasitic disease and preparation method thereof | |
| CN101972334B (en) | Traditional Chinese medicine preparation for preventing and treating infantile eczema and preparation method thereof | |
| CN1895261A (en) | Use of pokeroot saponin A in preparation medicine for treating rheumatoid arthritis | |
| CN1857502A (en) | Chinese medicine liniment for treating toothache and its preparing method | |
| CN114177231B (en) | Antipyretic pharmaceutical composition, antipyretic gel and preparation method | |
| CN1939465A (en) | Chinese-medicinal composition for treating fowl mycoplasmosis and mixed enteritis infection | |
| CN103893300B (en) | A kind of Chinese medicine composition treating cow endometritis and preparation method and application | |
| CN103861007B (en) | A kind of Chinese herbal compound preparation for the treatment of chicken diarrhea | |
| CN103191175A (en) | Diarrhoea-stopping traditional Chinese medicine composition, capsule and application thereof | |
| CN102688477B (en) | Medicinal composition for treating respiratory diseases of livestock | |
| CN111557998A (en) | Traditional Chinese medicine composition for treating skin diseases and preparation method and application thereof | |
| CN1219527C (en) | Ointment for curing acne and its preparation method | |
| CN109260333A (en) | A kind of ointment and preparation method thereof with promoting blood circulation toxin expelling effect | |
| CN104187658B (en) | Columba livia health care oral liquid and application thereof | |
| CN116036188B (en) | Traditional Chinese medicine composition for preventing and treating chicken coccidiosis as well as preparation method and application thereof | |
| CN100336535C (en) | Children health pectoral mixture for treating child wind and heat caused by exopathogen and its preparing method | |
| CN1256942C (en) | Application of dihydromyricetrin | |
| CN1267095C (en) | Application use of dihydromyricetrin | |
| CN106727926B (en) | Medicine for resisting hepatic fibrosis and treating liver cirrhosis and preparation method thereof | |
| CN1316980C (en) | Medicinal use of spanish moss of Chinese traditional medicine | |
| CN104971210A (en) | External lotion for treating tinea pedis and preparation method thereof | |
| CN110870909A (en) | Chinese and western medicine ointment for treating herpes zoster and preparation method thereof | |
| CN113893304A (en) | Chinese medicinal compound preparation for treating chicken synovial capsule mycoplasmosis | |
| CN104208168A (en) | Compound traditional Chinese medicine composition for treating poultry respiratory tract infection and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication |